Journal of Applied Toxicology · 2015 · 10 citations · 39 references
Life SciencesCell BiologyOncologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerBcl-2 Family ProteinsCancer Cell SignalingCytotoxic ChemotherapyAntineoplastic Drug TherapyApoptosis InductionBcl-2 Protein LocalizationOxidative Stress In CancerPro-apoptotic Bcl-2 ProteinsProapoptotic Bcl-2 ProteinsProtein Subcellular LocalizationSubcellular Protein Localization
Cancer chemotherapy remains one of the preferred therapeutic modalities against malignancies despite its damaging side effects. An expected outcome while utilizing chemotherapy is apoptosis induction. This is mainly regulated by a group of proteins known as the Bcl-2 family, usually found within the endoplasmic reticulum or the mitochondria. Recently, these proteins have been located in other sites and non-canonic functions have been unraveled. Bik is a pro-apoptotic protein, which becomes deregulated in cancer, and as apoptosis is associated with oxidative stress generation, our objective was to determine the subcellular localization of Bik either after a direct oxidative insult due to H2 O2 , or indirectly by cisplatin, an antineoplastic agent. Experiments were performed in two human transformed mammary gland cell lines MDA-MB-231 and MCF-7, and one non-tumorigenic epithelial cell line MCF-10A. Our results showed that in MCF-7, Bik is localized within the cytosol and that after oxidative stress treatment it translocates into the nucleus. However, in MDA-MB-231, Bik localizes in the nucleus and translocates to the cytosol. In MCF10A Bik did not change its cellular site after either treatment. Interestingly, MCF10A were more resistant to cisplatin than transformed cell lines. This is the first report showing that Bik is located in different cellular compartments depending on the cancer stage, and it has the ability to change its subcellular localization in response to oxidative stress. This is associated with increased sensitivity when exposed to toxic agents, thus rendering novel opportunities to study new therapeutic targets allowing the development of more active and less harmful agents.
39
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve, Koei Chin, Jane Fridlyand et al. · Cancer Cell · 2006 · 3.2K citations · Full text
Medicine, Cell Biology, Oncology +14
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text
Medicine, Gynecology, Oncology +14